3167 related items for PubMed ID: 16860172
1. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[Abstract] [Full Text] [Related]
2. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[Abstract] [Full Text] [Related]
3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[Abstract] [Full Text] [Related]
4. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
Figurski MJ, Nawrocki A, Pescovitz MD, Bouw R, Shaw LM.
Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
[Abstract] [Full Text] [Related]
5. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tönshoff B.
Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
[Abstract] [Full Text] [Related]
6. Mycophenolate pharmacokinetics in early period following lung or heart transplantation.
Ensom MH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD.
Ann Pharmacother; 2003 Dec; 37(12):1761-7. PubMed ID: 14632536
[Abstract] [Full Text] [Related]
7. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[Abstract] [Full Text] [Related]
8. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, Sabbatini M.
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[Abstract] [Full Text] [Related]
9. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA.
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[Abstract] [Full Text] [Related]
10. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DR, Tsai E, Vinks AA, Weber LT, Zimmerhackl LB.
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[Abstract] [Full Text] [Related]
11. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
Strong DK, Lai A, Primmett D, White CT, Lirenman DS, Carter JE, Hurley RM, Virji M, Ensom MH.
Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
[Abstract] [Full Text] [Related]
12. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients.
Hulin A, Blanchet B, Audard V, Barau C, Furlan V, Durrbach A, Taïeb F, Lang P, Grimbert P, Tod M.
Ther Drug Monit; 2009 Apr; 31(2):224-32. PubMed ID: 19214145
[Abstract] [Full Text] [Related]
13. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
Gelone DK, Park JM, Lake KD.
Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
[Abstract] [Full Text] [Related]
14. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[Abstract] [Full Text] [Related]
15. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
Cattaneo D, Merlini S, Baldelli S, Bartolini B, Nicastri A, Gotti E, Remuzzi G, Perico N.
Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
[Abstract] [Full Text] [Related]
16. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
Wang CH, Ko WJ, Chou NK, Wang SS.
Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
[Abstract] [Full Text] [Related]
17. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U, Ullrich S, Roskos M, Misselwitz J.
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[Abstract] [Full Text] [Related]
18. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
Clin Pharmacokinet; 2009 Apr; 48(11):745-58. PubMed ID: 19817503
[Abstract] [Full Text] [Related]
19. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[Abstract] [Full Text] [Related]
20. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.
Doesch AO, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Ehlermann P, Zugck C, Katus HA.
Transplant Proc; 2010 Dec; 42(10):4243-6. PubMed ID: 21168674
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
